- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04494451
Efficacy of Vitamin C on AKI Outcomes in Critically Ill Cirrhotics With Multidrug-resistant Bacterial Infections.
Efficacy of Vitamin C on AKI Outcomes in Critically Ill Cirrhotics With Multidrug-resistant Bacterial Infections- A Randomized Controlled Trial
In this prospective randomized controlled trial we aim to evaluate the impact of vitamin C on AKI outcomes in patients with cirrhosis and MDR infections. We also aim to evaluate the effects of iv vitamin c on systemic hemodynamics (cardiac output and systemic vascular resistive index, extravascular lung water and lung permeability index), endothelial function and coagulation, microcirculation (as assessed by lactate clearance and central venous oxygen saturation), mitochondrial function, 28-day mortality and vasopressor, ventilator and RRT free days in the ICU. The safety and side-effects of vitamin c would also be evaluated.
Patients with suspected (nosocomial acquisition) or proven MDR infections would be screened and randomized to two groups who meet the inclusion and exclusion criteria.
Group 1: Will receive iv vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 days along with iv antibiotics as per institutional protocol Group 2: iv antibiotics alone
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aim & Objectives Primary To evaluate the impact of vitamin C on AKI outcomes in patients with cirrhosis and MDR infections
Secondary Objectives To assess the effects on systemic hemodynamics (cardiac output and systemic vascular resistive index, extravascular lung water and lung permeability index) Impact of Vitamin C on endothelial function and coagulation Improvement in microcirculation as assessed by lactate clearance and central venous oxygen saturation To assess the effects on 28-day mortality. Improvement in SOFA scores in both groups Vasopressor, ventilator and RRT free days in the ICU Incidence of adverse effects in both groups Prevalence of vitamin C deficiency in cirrhotics with sepsis and impact of exogenous vitamin C in improving endogenous levels of ascorbate and norepinephrine levels Impact of vitamin C on oxidative stress by evaluation of mitochondrial bioenergetics
(B) Methodology Patients with suspected (nosocomial acquisition) or proven MDR infections would be screened and randomized to two groups as under Group 1: Will receive iv vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 days along with iv antibiotics as per institutional protocol Group 2: iv antibiotics alone All patients with nosocomial bacterial infections or septic shock would be screened for randomization would be considered for enrolment in the trial. Nosocomial infection would be defined as infections developing after 48 hours of hospitalization. Following this, patients meeting the inclusion and exclusion criteria will be screened and randomized to the two treatment groups. Standard of care for management of antibiotics, fluids and vasopressors would be as per institutional guidelines. At baseline, blood and urine sample would be stored for all patients for performing mitochondrial bioenergetics, endotoxin, proinflammatory cytokines (IL-6, IL-IB, TNF-alpha, MCP-1, IL-1O) and urine biomarkers (urine NGAL and cystatin C) and markers of endothelial dysfunction(von willebrand factor and ADAMTS). Following randomization patients would be allocated to receive intravenous vitamin C (1.5 g every 6 h or 25 mg/kg for 5 days) along with intravenous antibiotics
Study Population:
Patients with cirrhosis with MDR infections (nosocomial acquisition) or culture-proven
Study Design:
- A randomized controlled study.
- The study will be conducted on patients admitted to Department of Hepatology from June 2020 to December 2020 at ILBS, New Delhi
- Study group will comprise of patients critically ill cirrhotics with suspected or proven MDR infections
Study period
- The study will be conducted on patients admitted to Department of Hepatology from June 2020 to December 2020 at ILBS, New Delhi
- Study group will comprise of patients critically ill cirrhotics with MDR infections.
Sample Size calculation: Currently there are lack of studies investigating the incidence and outcomes of AKI in this context. The study will be designed as a pilot RCT with an aim to enrol 50 patients in each group.
The detailed cytokine profile, endotoxin assay, markers of endothelial dysfunction and bioenergetics would be performed in a subset of 15 patients in each group.
Intervention: IV Vitamin C
Monitoring and Assessment: Hourly till the patient is in the intensive care unit then every 7 days for 1 month
Statistical analysis
- All variables shall be expressed in mean (sd) or median (range)
- Variables will be compared by Mann- Whitney U test
- For Categorical variables we will use Chi-Square or Fisher's test
- Survival analysis will be done using Cox-proportional regression analysis
Actuarial probability of survival shall be calculated by Kaplan- Meier graph and compared by log- rank test.
Adverse Effects: Any allergic reactions, drop in hemoglobin or development of kidney stones
Stopping rule of the study: Any untoward adverse effects of the intervention.
Ethical issues in the study and plans to address these issue The study is designed to demonstrate the efficacy of intravenous vitamin C in improving AKI outcomes in cirrhotics with MDR infections. Vitamin C is been routinely used in this indication with no major adverse effects. However, head-to-head comparison is needed to identify the evidence and benefits of using this drug in this indication. Only minor side effects like nausea, diarrhea, abdominal bloating, cramps and precipitation of kidney stones have been observed with the drug.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Delhi
-
New Delhi, Delhi, India, 110070
- Institute of Liver & Biliary Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Critically ill cirrhotics with MDR infections
Exclusion Criteria:
- Patients with age less than 18 years
- Known severe cardiopulmonary disease (structural or valvular heart disease, coronary artery disease, COPD)
- Patients in DIC with platelets < 20,000 and INR > 4 or active bleeding
- Limitations of care (defined as refusal of cardiovascular and respiratory support modes) including "do not intubate" (DNI) status
- Current hospitalization > 15 days for patients with nosocomial acquisition of MDR at time of randomization
- Known allergy or contraindication to vitamin C (including previously or currently diagnosed primary hyperoxaluria and/or oxalate nephropathy, or known/suspected ethylene glycol ingestion,
- Known glucose-6-phosphate dehydrogenase (G6PD) deficiency)
- Use of vitamin C at a dose of > 1 gram daily within the 24 hours preceding first episode of qualifying organ dysfunction during a given ED or ICU admission
- Patients with HCC (beyond Milan) or extrahepatic malignancies
- Patients with HVOTO or EHPVO
- Pregnancy or active breastfeeding
- Current participation in another interventional research study
- Active or history of kidney stone
- History of chronic kidney disease or intrinsic kidney disease
- Patients already on maintenance hemodialysis prior to presentation
- Patients with refractory septic shock or hypoxemia (Pa02/Fio2 ratio <100)
- Extremely moribund patients with an expected life expectancy of less than 24 hours
- Failure to provide informed consent
- Patients with retroviral infection
- Patients with acute on chronic liver failure (APASL definition)
- Patients with urinary tract infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vitamin C + Standard Medical Treatment
vitamin C (25 mg/kg or max.
1.5 gram every 6 hourly) for maximum 5 days along with iv antibiotics as per institutional protocol along with iv antibiotics
|
vitamin C (25 mg/kg or max.
1.5 gram every 6 hourly) for maximum 5 day
iv antibiotics alone
|
Active Comparator: Standard Medical Treatment
iv antibiotics alone
|
iv antibiotics alone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AKI progression at day 5
Time Frame: Day 5
|
Day 5
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mortality in both groups
Time Frame: Day 28
|
Day 28
|
Time to reversal of AKI in both groups
Time Frame: Day 14
|
Day 14
|
Lactate clearance in both groups
Time Frame: 12 hours
|
12 hours
|
Lactate clearance in both groups
Time Frame: 24 hours
|
24 hours
|
Vasopressor, ventilator and days free of dialysis during ICU stay
Time Frame: Day 28
|
Day 28
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ILBS-Cirrhosis-35
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
-
The Cleveland ClinicRecruitingCirrhosis, LiverUnited States
-
University of PittsburghNational Institute on Drug Abuse (NIDA)CompletedCirrhosis, LiverUnited States
-
Beth Israel Deaconess Medical CenterAmerican Association for the Study of Liver Diseases FoundationCompleted
-
Asian Institute of Gastroenterology, IndiaCompletedCirrhosis, LiverIndia
-
Sherief Abd-ElsalamUnknown
-
Fundació Institut de Recerca de l'Hospital de la...Spanish Clinical Research Network - SCReNWithdrawn
Clinical Trials on Vit C
-
PepsiCo Global R&DFood and Nutrition Research Institute, PhilippinesCompleted
-
Benha UniversityZagazig University; Hawaa Fertility CenterCompleted
-
Cairo UniversityEnrolling by invitationNutritional Rickets | Bone Turnover Rate DisorderEgypt
-
Medical University of ViennaUnknownIschemia Reperfusion InjuryAustria
-
University Hospital, MontpellierHospital Clinical Research Project 2010; Association Amis FSH France; FSH Dutch...CompletedFacioscapulohumeral Muscular DystrophyFrance
-
Chulalongkorn UniversityCompletedThe Effect of Exercises on Physiological Changes and Clinical Symptoms in Allergic Rhinitis PatientsAllergic RhinitisThailand
-
Hospital Juarez de MexicoRecruitingEnterocutaneous FistulasMexico
-
Sun Yat-sen UniversityRecruitingCongenital CataractChina
-
Vifor (International) Inc.FortreaCompletedSickle Cell DiseaseUnited States, France, Greece, Lebanon, United Kingdom
-
University of LouisvilleNorton Healthcare; Cumberland PharmaceuticalsCompletedAutism | Severe Behavior DisorderUnited States